8,389 Shares in DaVita Inc. $DVA Acquired by Fieldview Capital Management LLC

Fieldview Capital Management LLC acquired a new position in DaVita Inc. (NYSE:DVA) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 8,389 shares of the company’s stock, valued at approximately $953,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Elevation Wealth Partners LLC increased its holdings in DaVita by 147.3% in the fourth quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock worth $31,000 after buying an additional 165 shares during the last quarter. Canada Pension Plan Investment Board acquired a new position in DaVita in the second quarter worth approximately $43,000. Kestra Advisory Services LLC acquired a new position in DaVita in the fourth quarter worth approximately $45,000. iSAM Funds UK Ltd acquired a new position in DaVita in the third quarter worth approximately $46,000. Finally, Stance Capital LLC acquired a new position in DaVita in the third quarter worth approximately $47,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

Insider Buying and Selling at DaVita

In other news, CFO Joel Ackerman sold 51,471 shares of the stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total value of $9,887,579.10. Following the completion of the sale, the chief financial officer directly owned 132,434 shares of the company’s stock, valued at approximately $25,440,571.40. This represents a 27.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.50% of the company’s stock.

DaVita Stock Down 0.2%

Shares of DVA stock opened at $208.31 on Monday. DaVita Inc. has a 12 month low of $101.00 and a 12 month high of $211.80. The business’s 50 day moving average is $176.13 and its two-hundred day moving average is $146.28. The company has a market cap of $13.37 billion, a PE ratio of 19.32, a price-to-earnings-growth ratio of 0.68 and a beta of 0.91.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, beating the consensus estimate of $2.33 by $0.54. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The company had revenue of $3.42 billion for the quarter, compared to the consensus estimate of $3.36 billion. During the same quarter last year, the company posted $2.00 earnings per share. The company’s revenue for the quarter was up 6.0% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities analysts expect that DaVita Inc. will post 15.07 EPS for the current fiscal year.

Analyst Ratings Changes

DVA has been the topic of a number of research reports. Weiss Ratings restated a “hold (c+)” rating on shares of DaVita in a report on Monday, June 8th. Barclays increased their price target on DaVita from $158.00 to $194.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. UBS Group increased their price target on DaVita from $190.00 to $235.00 and gave the company a “buy” rating in a report on Thursday, May 7th. TD Cowen increased their price target on DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a report on Monday, May 11th. Finally, Wall Street Zen upgraded DaVita from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $199.17.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.